Literature DB >> 30479000

Diverse roles of RNA-binding proteins in cancer traits and their implications in gastrointestinal cancers.

Kiyoshi Masuda1, Yuki Kuwano2.   

Abstract

Gene expression patterns in cancer cells are strongly influenced by posttranscriptional mechanisms. RNA-binding proteins (RBPs) play key roles in posttranscriptional gene regulation; they can interact with target mRNAs in a sequence- and structure-dependent manner, and determine cellular behavior by manipulating the processing of these mRNAs. Numerous RBPs are aberrantly deregulated in many human cancers and hence, affect the functioning of mRNAs that encode proteins, implicated in carcinogenesis. Here, we summarize the key roles of RBPs in posttranscriptional gene regulation, describe RBPs disrupted in cancer, and lastly focus on RBPs that are responsible for implementing cancer traits in the digestive tract. These evidences may reveal a potential link between changes in expression/function of RBPs and malignant transformation, and a framework for new insights and potential therapeutic applications. This article is categorized under: RNA in Disease and Development > RNA in Disease RNA Interactions with Proteins and Other Molecules > Protein-RNA Interactions: Functional Implications.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  RNA-binding protein; gastrointestinal cancer; posttranscriptional gene regulation

Year:  2018        PMID: 30479000     DOI: 10.1002/wrna.1520

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev RNA        ISSN: 1757-7004            Impact factor:   9.957


  33 in total

1.  Inherent conformational plasticity in dsRBDs enables interaction with topologically distinct RNAs.

Authors:  Harshad Paithankar; Guneet Singh Tarang; Firdousi Parvez; Aniket Marathe; Manali Joshi; Jeetender Chugh
Journal:  Biophys J       Date:  2022-02-05       Impact factor: 4.033

2.  Development and validation of novel prognostic models based on RNA-binding proteins in breast cancer.

Authors:  Wei Fan; Jun Ding; Shushu Liu; Wei Zhong
Journal:  J Int Med Res       Date:  2022-06       Impact factor: 1.573

3.  Development and Validation of a RNA Binding Protein-Associated Prognostic Model for Hepatocellular Carcinoma.

Authors:  Ming Wang; Feng Jiang; Ke Wei; Jimei Wang; Guoping Zhou; Chuyan Wu; Guoyong Yin
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

4.  Integrated Analysis of the Prognosis-Associated RNA-Binding Protein Genes and Candidate Drugs in Renal Papillary Cell Carcinoma.

Authors:  Silin Jiang; Xiaohan Ren; Shouyong Liu; Zhongwen Lu; Aiming Xu; Chao Qin; Zengjun Wang
Journal:  Front Genet       Date:  2021-02-12       Impact factor: 4.599

5.  Clinical characteristics and prognostic value of MEX3A mRNA in liver cancer.

Authors:  Dingquan Yang; Yan Jiao; Yanqing Li; Xuedong Fang
Journal:  PeerJ       Date:  2020-01-21       Impact factor: 2.984

6.  Integral Analysis of the RNA Binding Protein-associated Prognostic Model for Renal Cell Carcinoma.

Authors:  Xin Qin; Zhengfang Liu; Keqiang Yan; Zhiqing Fang; Yidong Fan
Journal:  Int J Med Sci       Date:  2021-01-01       Impact factor: 3.738

7.  Integrated Analysis of the Functions and Prognostic Values of RNA Binding Proteins in Lung Squamous Cell Carcinoma.

Authors:  Wei Li; Xue Li; Li-Na Gao; Chong-Ge You
Journal:  Front Genet       Date:  2020-03-05       Impact factor: 4.599

8.  Development and validation of a RNA binding protein-associated prognostic model for lung adenocarcinoma.

Authors:  Wei Li; Li-Na Gao; Pei-Pei Song; Chong-Ge You
Journal:  Aging (Albany NY)       Date:  2020-02-22       Impact factor: 5.682

9.  Development and validation of a RNA binding protein gene pair-associated prognostic signature for prediction of overall survival in hepatocellular carcinoma.

Authors:  Chunmiao Kang; Xuanhui Jia; Hongsheng Liu
Journal:  Biomed Eng Online       Date:  2020-09-01       Impact factor: 2.819

10.  Development and Validation of an RNA-Binding Protein-Based Prognostic Model for Ovarian Serous Cystadenocarcinoma.

Authors:  Yunan He; Sen Zeng; Shunjie Hu; Fengqian Zhang; Nianchun Shan
Journal:  Front Genet       Date:  2020-10-15       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.